Le GLP-1 est une hormone physiologique exerant plusieurs effets sur la rgulation du glucose et de lapptit, ainsi que sur le systme cardiovasculaire ou encore le mtabolisme osseux
This reflects the chronic biology of obesity rather than a failure of the individual and reinforces that long-term treatment is often needed
Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Efficacy and Safety of Injectable Semaglutide in Indian Patients with Type 2 Diabetes: Findings from a Phase III Study Presented at IDS 2026 A recent Indian Phase III randomized open-label study has demonstrated that Sun Pharma's injectable semaglutide is non-inferior to international reference innovator semaglutide (Ozempic , Novo Nordisk) , showing comparable reductions in HbA1c, blood glucose levels, and body weight, along with a similar safety profile in Indian patients with uncontrolled type 2 diabetes mellitus (T2DM)
Common reported effects include nausea, upset stomach, and digestive discomfort, which often improve as the body adjusts to the medication
The GLP-1 trend appears to present three distinct investment opportunities
